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Case Report
Introduction
Osmotic demyelination syndrome (ODS), formerly called as 
central pontine myelinolysis from rapid hyponatremia cor-
rection, was first described by Adams et al.1 Hyponatremia is 
the most common electrolyte abnormality encountered in the 
clinical practice with a reported prevalence of 9% to 31% for 
a serum sodium (Na) <130 mEq/L and 0.03% to 0.49% for 
serum Na <116 mEq/L.2,3 A study with National Health and 
Nutrition Examination Survey data reported a prevalence of 
1.72% among the United States general population.4 The 
annual health care burden of hyponatremia is estimated to be 
1.6 billion to 3.6 billion dollars.5 Human brains adaptation to 
reduce the risk of cerebral edema from hypotonic hyponatre-
mia itself makes it vulnerable to osmotic stress that develops 
from rapid hyponatremia correction. The incidence of ODS is 
reported to be very low at 0.5% to 2% in the general popula-
tion and 10% among patients undergoing liver transplanta-
tion.6-9 Most occurred among subjects with a serum sodium 
<120 mEq/L and a sodium correction of >10 to 12 mEq/L 
in the initial 24 hours of presentation.8-12 Despite its low 
incidence, given significant morbidity and mortality asso-
ciated, it is still recommended to avoid the rapid correction 
of hyponatremia. The recommended rate of hyponatremia 
correction is 4 to 6 mEq/L in 24 hours. Among subjects with 
severe symptomatic hyponatremia, this correction should be 
achieved in the initial 4 to 6 hours with a maximum correc-
tion rate not exceeding 8 mEq/L within 24 hours.13,14 We 
hereby report a case of azotemia with severe hyponatremia in 
which sodium correction occurred rapidly devoid of any 
neurological sequelae.
Case Report
A 37-year-old man with a past medical history of pancreati-
tis, type 2 diabetes mellitus on insulin, and ulcerative colitis 
was brought to the emergency department with complaints 
of nausea, vomiting, and diarrhea for a 1-week duration 
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Abstract
Hyponatremia is the most common electrolyte abnormality encountered both in the inpatient and outpatient clinical settings 
in the United States. Rapid correction leads to a deranged cerebral osmotic gradient causing osmotic demyelination syndrome. 
Coexisting azotemia is considered to be protective against osmotic demyelination syndrome owing to its counteractive 
effect on osmolarity change that occurs with rapid hyponatremia correction. In this article, we report the case of a 37-year-
old male who presented with altered mentation, acute azotemia, and severe electrolyte derangements, with serum blood 
urea nitrogen 160 mg/dL, creatinine 8.4 mg/dL, sodium 107 mEq/L, potassium 6.1 mEq/L, bicarbonate 7 mEq/L, and anion 
gap of 33. Given refractory hyperkalemia with electrocardiogram changes, emergent dialysis was performed. Despite our 
efforts to avoid rapid correction, serum sodium was corrected to 124 mEq/L and blood urea nitrogen decreased to 87 mg/
dL at the end of the 5-hour dialysis session. Fortunately, hospital course and 4-week post-discharge clinic follow-ups were 
uncomplicated with no neurological sequela confirmed by neurological examination and magnetic resonance imaging.
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followed by anuria for 48 hours prior to this presentation. 
Vital signs on presentation include a temperature of 36.3°C, 
blood pressure of 103/60 mm Hg, heart rate of 79 beats per 
minute, and respiratory rate of 16 breaths per minute, satu-
rating at 100% on room air. On examination, the patient 
appeared somnolent with dry mucous membranes and loss of 
skin turgor. Limited neurologic examination was unremark-
able. Comprehensive serum drug screen was negative. 
Laboratory data are relevant for serum blood urea nitrogen 
160 mg/dL, creatinine 8.4 mg/dL, Na 107 mEq/L, potassium 
6.1 mEq/L, bicarbonate 7 mEq/L, anion gap of 33, glucose 
169 mg/dL, and measured serum osmolality of 297 mOsm/L. 
Electrocardiogram showed normal sinus rhythm with peak 
T-waves. Urine studies revealed Na <10 mEq/L, creatinine 
286 mg/dL, and osmolality of 311 mOsm/L, with hyaline 
casts and fractional excretion of sodium of 0.6%. No prior 
history of renal disease noted, and renal ultrasound was unre-
markable. Given refractory and worsening hyperkalemia, 
worsening uremia, and acidosis, emergent dialysis was 
planned. However, the lowest sodium bath available for dial-
ysis being 130 mEq, 0.45% normal saline was infused during 
the dialysis session to prevent rapid sodium correction. He 
received one session of hemodialysis and serum Na increased 
to 124 mEq/L and blood urea nitrogen decreased to 87 mg/
dL during the 5-hour dialysis session. The patient’s menta-
tion gradually improved, fully alert, awake, and oriented 
without any immediate neurological deficits. Detailed neu-
rological examination performed prior to discharge was also 
unremarkable, including normal cranial nerve examination, 
muscle strength, and deep tendon reflexes, sensory function, 
gait, and coordination. Both T1- and T2-weighted imaging 
sequences on magnetic resonance imaging (MRI) scan 
performed 7 days after the rapid correction event was unre-
markable. The patient’s neurological examination remained 
unremarkable on his 4-week posthospital clinic follow-up.
Discussion
Osmotic demyelination syndrome or osmotic myelinolysis 
was first described in alcoholics and in malnourished by 
Adams et al in 1959; however, the etiological role of sodium 
was not identified at that time.1 The etiological role of sodium 
correction rate in causing myelinolysis was confirmed later 
in animal models.15 Serum Na is the primary determinant of 
serum tonicity. As hyponatremia develops, brain cells adapt 
by the efflux of organic and inorganic osmolytes to avoid 
relative hypotonicity. Efflux of inorganic osmolytes like 
potassium and chloride occurs within minutes to hours, 
which is followed by a delayed efflux of organic osmolytes 
like amino acids over the next few days.16,17 During the 
hyponatremia correction, brain cells should adapt to relative 
hypertonicity caused by increasing extracellular sodium con-
centrations. This adaption occurs by the influx of osmolytes 
back into brain cells. As organic solutes take longer time to 
reaccumulate, in the event of a rapid correction, delayed 
reaccumulation of organic solutes leads to a relatively hyper-
tonic serum compared with brain cells eventually causing an 
efflux of water leading to ODS.18
On the other hand, rapid correction of azotemia in dialy-
sis leads to cerebral edema owing to slower diffusion of 
urea across the blood-brain barrier.19 In animal studies, the 
presence of concurrent azotemia decreased the incidence 
and severity of myelinolysis with rapid hyponatremia 
correction.16 Acute azotemia being hypertonic state triggers 
the intracellular accumulation of organic osmolytes as an 
adaptive mechanism to prevent water influx into brain 
cells.20 This also leads to the synthesis of transporters for 
organic osmolytes facilitating rapid redistribution with azo-
temia correction.21 The increased intracellular concentra-
tion of cerebrospinal fluid urea and other organic osmolytes 
seen with azotemia state partially counteracts the extracel-
lular hyperosmolarity that develops with rapid hyponatre-
mia correction.
The above-mentioned counteracting mechanism of azote-
mia and hyponatremia on cerebral osmolarity, when coexist, 
was postulated to have a possible protective effect in prevent-
ing ODS from rapid sodium correction.16,21,22 One such obser-
vation was from retrospective analysis done by Dhrolia 
et al supporting the protective effect of azotemia.23 In their 
retrospective analysis, none of their 52 subjects with azo-
temia and hyponatremia developed ODS despite a mean 
24-hour sodium correction by 15.4 (±3.4). However, in 
this analysis, neurological examination was reported imme-
diately after dialysis and only 2 out of 52 subjects had MRI 
performed. MRI is the recommended imaging to diagnose 
ODS. Characteristic findings include symmetric signal 
hyperintensity in the central pons on T2-weighted and fluid 
attenuation inversion recovery sequences with correspond-
ing decreased T1-weighted signal.24,25 Clinical manifesta-
tions of myelinolysis are usually not apparent immediately 
and are often delayed by up to 5 to 6 days after rapid sodium 
correction. Absence of MRI findings and delayed neurologic 
examination in that study, it would be a dangerous assump-
tion to conclude that uremia had prevented ODS among all 
their study subjects.26-28 Fortunately, our case did not have 
any neurologic sequelae confirmed by delayed neurological 
testing and MRI imaging. Nevertheless, not all patients with 
azotemia and hyponatremia can be protective against ODS 
and clinical models to pinpoint at-risk populations for ODS 
are not yet developed. ODS among uremic subjects with 
rapid sodium correction has been reported and confirmed by 
delayed neurological examination and MRI.26,29-31 Until fur-
ther evidence, it will be premature to conclude that uremia 
prevents ODS, as this might lead a false sense of assurance 
among the physicians and not to follow any preventive mea-
sures to avoid rapid sodium correction. Given the detrimen-
tal effects of ODS and lack of sustained evidence on the 
protective effect of azotemia, physicians should follow all 
possible precautions to avoid rapid sodium correction. Few 
such measures include reduction of dialysate sodium, 
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infusion of hypotonic saline with dialysis, increasing dialysis 
duration, or perform intermittent short duration sessions if 
clinically feasible.
Osmotic demyelination syndrome is a rare preventable 
complication of rapid hyponatremia correction and is associ-
ated with significant morbidity and mortality. Though azote-
mia was proposed to be protective, not all previously reported 
cases with azotemia were fortunate enough to be exempt from 
developing ODS. Given the detrimental effects of this pre-
ventable condition, until further evidence, physicians should 
still follow all the necessary steps to avoid rapid hyponatre-
mia correction even among cases with concurrent azotemia.
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